Cargando…

Alectinib treatment improves photodynamic therapy in cancer cell lines of different origin

BACKGROUND: Photodynamic therapy with a photosensitizer such as protoporphyrin-IX, a light sensitive metabolite of heme synthesis, is a highly selective treatment for various carcinomas. In previous studies, we found a significant down regulation of the relevant enzyme ferrochelatase in gastrointest...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gillissen, Bernhard, Richter, Antje, Essmann, Frank, Kemmner, Wolfgang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8404354/ https://www.ncbi.nlm.nih.gov/pubmed/34461853 http://dx.doi.org/10.1186/s12885-021-08667-x

Ejemplares similares

Mcl-1 determines the Bax dependency of Nbk/Bik-induced apoptosis
por: Gillissen, Bernhard, et al.
Publicado: (2007)

First-line alectinib for ALK-positive lung cancer: is there room for further improvement?
por: Addeo, Alfredo, et al.
Publicado: (2018)

Focus on Alectinib and Competitor Compounds for Second-Line Therapy in ALK-Rearranged NSCLC
por: Tran, Phu N., et al.
Publicado: (2016)

Comparison of Alectinib/Crizotinib Data in First-Line Therapy in Patients with Anaplastic Lymphomakinase-Positive Nonsmall Cell Lung Carcinoma with Poor Prognostic Features for Alectinib
por: Katgı, Nuran, et al.
Publicado: (2023)

Targeted therapy of the XIAP/proteasome pathway overcomes TRAIL-resistance in carcinoma by switching apoptosis signaling to a Bax/Bak-independent ‘type I' mode
por: Gillissen, B, et al.
Publicado: (2013)

Alectinib-Induced Erythema Multiforme and Successful Rechallenge with Alectinib in a Patient with Anaplastic Lymphoma Kinase-Rearranged Lung Cancer
por: Kimura, Tatsuo, et al.
Publicado: (2016)

Effect of Hepatic Impairment on the Pharmacokinetics of Alectinib
por: Morcos, Peter N., et al.
Publicado: (2018)

Contribution of BH3-domain and Transmembrane-domain to the Activity and Interaction of the Pore-forming Bcl-2 Proteins Bok, Bak, and Bax
por: Stehle, Daniel, et al.
Publicado: (2018)

Cost-effectiveness of alectinib compared to crizotinib for the treatment of first-line ALK+ advanced non-small-cell lung cancer in France
por: Sivignon, Marine, et al.
Publicado: (2020)

Enhanced Apoptosis and Loss of Cell Viability in Melanoma Cells by Combined Inhibition of ERK and Mcl-1 Is Related to Loss of Mitochondrial Membrane Potential, Caspase Activation and Upregulation of Proapoptotic Bcl-2 Proteins
por: Peng, Zhe, et al.
Publicado: (2023)

Sequential treatment with alectinib in crizotinib-resistant non-small-cell lung cancer
por: Majumdar, Swaratika, et al.
Publicado: (2018)

Case report: Indolent drug-related pneumonitis with alectinib therapy in the treatment of non-small cell lung cancer
por: Chen, Xianmeng, et al.
Publicado: (2022)

Successful alectinib treatment after crizotinib‐induced interstitial lung disease
por: Fujiuchi, Satoru, et al.
Publicado: (2016)

Successful treatment with crizotinib after alectinib-induced interstitial lung disease
por: Zhu, Ning, et al.
Publicado: (2021)

Metabolites of alectinib in human: their identification and pharmacological activity
por: Sato-Nakai, Mika, et al.
Publicado: (2017)

Autophagy Regulation and Photodynamic Therapy: Insights to Improve Outcomes of Cancer Treatment
por: Martins, Waleska K., et al.
Publicado: (2021)

How to improve photodynamic therapy-induced antitumor immunity for cancer treatment?
por: Zhang, Min, et al.
Publicado: (2022)

Efficient Photodynamic Therapy on Human Retinoblastoma Cell Lines
por: Walther, Jan, et al.
Publicado: (2014)

Calreticulin as Cancer Treatment Adjuvant: Combination with Photodynamic Therapy and Photodynamic Therapy-Generated Vaccines
por: Korbelik, Mladen, et al.
Publicado: (2015)

Phase II Trial of the Combination of Alectinib with Bevacizumab in Alectinib Refractory ALK-Positive Nonsquamous Non-Small-Cell Lung Cancer (NLCTG1501)
por: Watanabe, Satoshi, et al.
Publicado: (2022)

Photodynamic effects of haematoporphyrin derivative on synchronized and asynchronous cells of different origin.
por: Christensen, T., et al.
Publicado: (1981)

Potentiality, Limitations, and Consequences of Different Experimental Models to Improve Photodynamic Therapy for Cancer Treatment in Relation to Antiangiogenic Mechanism
por: Majerník, Martin, et al.
Publicado: (2020)

Photodynamic Therapy for the Treatment of Glioblastoma
por: Cramer, Samuel W., et al.
Publicado: (2020)

Successful Treatment with Ensartinib After Alectinib-induced Hyperbilirubinemia in ALK-Positive NSCLC
por: Peng, Ling, et al.
Publicado: (2021)

Progressive renal insufficiency related to ALK inhibitor, alectinib
por: Nagai, Kojiro, et al.
Publicado: (2018)

Development of Alectinib-Suspended SNEDDS for Enhanced Solubility and Dissolution
por: Park, Eun Ji, et al.
Publicado: (2022)

Photodynamic Therapy-Adjunctive Therapy in the Treatment of Prostate Cancer
por: Osuchowski, Michał, et al.
Publicado: (2022)

Alectinib in the treatment of ALK-positive non-small cell lung cancer: an update on its properties, efficacy, safety and place in therapy
por: Vavalà, Tiziana, et al.
Publicado: (2018)

Pharmacometric analyses of alectinib to facilitate approval of the optimal dose for the first‐line treatment of anaplastic lymphoma kinase–positive non‐small cell lung cancer
por: Hsu, Joy C., et al.
Publicado: (2021)

Efficacy of gilteritinib in comparison with alectinib for the treatment of ALK‐rearranged non‐small cell lung cancer
por: Ando, Chihiro, et al.
Publicado: (2023)

The BCL-2 inhibitor ABT-199/venetoclax synergizes with proteasome inhibition via transactivation of the MCL-1 antagonist NOXA
por: Weller, Sandra, et al.
Publicado: (2022)

The Current Status of Photodynamic Therapy in Cancer Treatment
por: Jiang, Wenqi, et al.
Publicado: (2023)

STRN-ALK Fusion–Positive Case of Breast Cancer With Response to Alectinib
por: Kelly, Andrew D., et al.
Publicado: (2021)

Nanomaterials as carriers to improve the photodynamic antibacterial therapy
por: Liu, Houhe, et al.
Publicado: (2022)

The efficacy and safety of alectinib in the treatment of ALK+ NSCLC: a systematic review and meta-analysis
por: Fan, Junsheng, et al.
Publicado: (2018)

Alectinib treatment response in lung adenocarcinoma patient with novel EML4‐ALK variant
por: Song, Peng, et al.
Publicado: (2018)

Progress in the photodynamic therapy treatment of Leishmaniasis
por: Vital-Fujii, D.G., et al.
Publicado: (2021)

Photodynamic Therapy for the Treatment of Fungal Infections
por: Wu, Xuelin, et al.
Publicado: (2022)

No-Dose Photodynamic Therapy Against Half-Dose Photodynamic Therapy for Treatment of Central Serous Chorioretinopathy
por: Servillo, Andrea, et al.
Publicado: (2023)

The Contemporary Role of Photodynamic Therapy in the Treatment of Pachychoroid Diseases
por: Iu, Lawrence P. L., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_n16at63q5fuh4hrm2rphs2jm4p